GlassScriptPhysician profile
Mitchell Craig Preston
NPI 1417955766
$539.88
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $172 · 2021: $29.69.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $142.64 | 2019-2020 | |
| Pfizer INC. | $77.38 | 2019-2020 | |
| Glaxosmithkline, LLC. | $77.24 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.07 | 2019-2020 | |
| Amgen INC. | $45.02 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.52 | 2020 | |
| Abbvie INC. | $15.86 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.60 | 2020 | |
| Genentech USA, INC. | $14.33 | 2019 | |
| Grifols USA, LLC | $13.77 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.64 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.58 | 2019 | |
| Supernus Pharmaceuticals, INC. | $11.85 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.38 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Preston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.